跳至主要内容
临床试验/JPRN-UMIN000031758
JPRN-UMIN000031758已完成未知

The verification study of improvements in cognitive functions: A randomized double-blind placebo-controlled trial - The verification study of improvements in cognitive functions

ORTHOMEDICO Inc.0 个研究点目标入组 44 人开始时间: 2018年10月31日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
44

研究概览

简要总结

Sekikawa T, Kizawa Y, Li Y, Takara T. Cognitive function improvement with astaxanthin and tocotrienol intake: a randomized, double-blind, placebo-controlled study. J Clin Biochem Nutr 2020; 67(3): 307-316

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. At least one previous medical history of malignant tumor, heart failure or myocardial infarction 2. Undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver failure, kidney failure, cerebrovascular disease, rheumatism, diabetes mellitus, dyslipidemia, hypertension or any other chronic diseases 3. Subjects who have dementia 4. Subjects who have mental health issues such as depression disorder, depression disorder, attention deficit/hyperactivity disorder (ADHD), or other issues 5. Currently taking medications (include herbal medicines), "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage 6. Subjects who take supplements related to improving cognitive functions, such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), ginkgo leaf extract, tocotrienol, astaxanthin, gamma-aminobutyric acid (GABA), and phosphatidylserine in daily 7. Subjects who are allergic to medicines and/or the test food related products 8. Subjects who are pregnant, lactation, and planning to become pregnant 9. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial 10. Subjects who are judged as ineligible to participate in the study by the physician

研究者

相似试验

The verification study of improvements in cognitive... | 临床试验